Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC by Travis, Ruth C. et al.
ORIGINAL PAPER
Prediagnostic concentrations of plasma genistein and prostate
cancer risk in 1,605 men with prostate cancer and 1,697 matched
control participants in EPIC
Ruth C. Travis • Naomi E. Allen • Paul N. Appleby • Alison Price •
Rudolf Kaaks • Jenny Chang-Claude • Heiner Boeing • Krasimira Aleksandrova •
Anne Tjønneland • Nina Føns Johnsen • Kim Overvad • J. Ramo ´n Quiro ´s •
Carlos A. Gonza ´lez • Esther Molina-Montes • Maria Jose ´ Sa ´nchez •
Nerea Larran ˜aga • Jose ´ Marı ´a Huerta Castan ˜o • Eva Ardanaz • Kay-Tee Khaw •
Nick Wareham • Antonia Trichopoulou • Tina Karapetyan • Snorri Bjorn Rafnsson •
Domenico Palli • Vittorio Krogh • Rosario Tumino • Paolo Vineis •
H. Bas Bueno-de-Mesquita • Pa ¨r Stattin • Mattias Johansson • Veronika Fedirko •
Teresa Norat • Afshan Siddiq • Elio Riboli • Timothy J. Key
Received: 23 November 2011/Accepted: 27 April 2012/Published online: 22 May 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Purpose Data from prospective epidemiological studies
in Asian populations and from experimental studies in
animals and cell lines suggest a possible protective asso-
ciation between dietary isoﬂavones and the development of
prostate cancer. We examined the association between
circulating concentrations of genistein and prostate cancer
risk in a case–control study nested in the European Pro-
spective Investigation into Cancer and Nutrition.
Methods Concentrations of the isoﬂavone genistein were
measured in prediagnostic plasma samples for 1,605
prostate cancer cases and 1,697 matched control
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DOI 10.1007/s10552-012-9985-yparticipants. Relative risks (RRs) for prostate cancer in
relation to plasma concentrations of genistein were esti-
mated by conditional logistic regression.
Results Plasma genistein concentrations were not asso-
ciated with prostate cancer risk; the multivariate relative
risk for men in the highest ﬁfth of genistein compared with
men in the lowest ﬁfth was 1.00 (95 % conﬁdence inter-
val: 0.79, 1.27; p linear trend = 0.82). There was no evi-
dence of heterogeneity in this association by age at blood
collection, country of recruitment, or cancer stage or his-
tological grade.
Conclusion Plasma genistein concentration was not
associated with prostate cancer risk in this large cohort of
European men.
Keywords Prospective  Prostate cancer  Plasma 
Isoﬂavone  Genistein  Phyto-estrogen
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Introduction
Results from several prospective epidemiological studies
of dietary isoﬂavone or soy intake and prostate cancer risk
in Asian populations, as well as from experimental studies
in animal models and in cell lines, suggest a possible
protective association between dietary isoﬂavones and the
development of prostate cancer [1–3]. The contrasting null
ﬁndings in the majority of observational studies in non-
Asian populations have been partly attributed to the typi-
cally lower amount of isoﬂavones consumed in those
populations [2]. However, it is difﬁcult to exclude residual
confounding by some other aspect of a traditional Asian
lifestyle as an explanation for the apparent protective
associations observed in Asian populations.
The direct measurement of isoﬂavones in the circula-
tion, as opposed to dietary isoﬂavone or soy intake, pro-
vides an alternative measure of exposure that captures
isoﬂavone from all sources, including intake that may be
inadequately represented in food composition databases [4]
and isoﬂavones that are a product of metabolism by gut
microﬂora [5]. However, published data from large-scale
prospective investigations of circulating concentrations of
isoﬂavones in relation to risk are limited and inconsistent
[6, 7]. An earlier investigation of plasma phyto-estrogens
in 950 men with prostate cancer and 1,042 matched control
participants from the European Prospective Investigation
into Cancer and Nutrition [8] found a possible inverse
association with prediagnostic plasma concentrations of
genistein, but no evidence of an association with daidzein,
equol, or the lignans enterolactone and enterodiol. Here, we
describe the results from an extension of this study,
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123including 1,605 men with incident prostate cancer and
1,697 matched control participants, in which we sought to
conﬁrm this association with genistein and to estimate
more precisely the risk of prostate cancer, overall and
subdivided by tumor characteristics and other factors.
Materials and methods
Between 1992 and 2000, approximately 500,000 individ-
uals (150,000 men) were recruited into the European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
from 23 centers in 10 European countries. The methods of
recruitment and study design have been described in detail
elsewhere [9]. Participants completed an extensive ques-
tionnaire on dietary and non-dietary factors at recruitment,
and about 400,000 individuals (of whom 137,000 were
men) also provided blood samples. All participants gave
written consent for the research, and approval for the study
was obtained from the Internal Review Board of the
International Agency for Research on Cancer (Lyon,
France) and from the local ethics committees in partici-
pating countries.
The present study includes prostate cancer cases
occurring after blood collection and individually matched
male control participants from the eight participating
countries that recruited men: Denmark, Germany, Greece,
Italy, the Netherlands, Spain, Sweden, and the United
Kingdom (UK). Men were eligible for this analysis if they
had information available on the date of blood donation
and did not have a history of cancer (except non-melanoma
skin cancer) at the time of the blood collection.
Follow-up for diagnosis of prostate cancer is provided
through record linkage with population-based cancer reg-
istries in six of the participating countries: Denmark, Italy,
the Netherlands, Spain, Sweden, and the UK. In Germany
and Greece, follow-up is active and is achieved through
checks of insurance records and cancer and pathology
registries as well as via self-reported questionnaires; self-
reported incident cancers are veriﬁed through medical
records. Data on vital status in most EPIC study centers
were collected from mortality registries at the regional or
national level, in combination with data collected by active
follow-up (Greece). The 10th Revision of the International
Statistical Classiﬁcation of Diseases, Injuries and Causes of
Death (ICD) was used, and cancer of the prostate was
deﬁned as code C61.
We previously reported our ﬁndings from measurements
in samples from 950 men with prostate cancer (diagnosed
between 1999 and 2003) and 1,042 matched control par-
ticipants that were assayed in 2007 [8]. In the current study,
we combined data from those 1992 individuals (designated
as phase 1) with 655 additional men who had been
subsequently diagnosed with prostate cancer (up to 2006)
and their 655 matched control participants (designated
phase 2), whose samples were assayed in 2009. Samples
for phase 2 were available for EPIC participants from six of
the eight countries in phase 1 (phase 2 samples from
Denmark and Sweden were not available for the current
study).
Case patients were men who were diagnosed with
prostate cancer after the date of blood collection and before
the end of the study period, deﬁned for each study center
by the latest date of follow-up. Laboratory measures for the
current analysis were available for a total of 1,605 cases:
288 cases in Denmark, 412 in Germany, 40 in Greece, 146
in Italy, 50 in the Netherlands, 201 in Spain, 94 in Sweden,
and 364 in the UK.
Data on the stage and grade of disease at diagnosis were
collected from each center, where possible. A total of 1,108
cases (69.0 %) had information on tumor stage; of these,
792 (71.5 %) were classiﬁed as localized (tumor [T]-node
[N]-metastasis [M] categories T0 or T1 or T2 and N0 or
NX and M0, or stage coded in recruitment center as
localized), and 316 (28.5 %) were classiﬁed as advanced
(T3 or T4, N1?, M1, or some combination of these, or
stage coded in recruitment center as metastatic). Informa-
tion on histological grade was available for 1,129 cases
(70.3 %); of these, 941 (83.3 %) were classiﬁed as low
grade (Gleason sum\8 or equivalent, i.e., coded as mod-
erately or as well differentiated) and 188 (16.7 %) were
classiﬁed as high grade (Gleason sum C8 or equivalent,
i.e., coded as poorly differentiated or as undifferentiated).
Each case patient was matched to one control participant
(with the exception of case patients from Umea ˚ who were
matched to two control participants), selected at random
among appropriate risk sets consisting of all male cohort
members alive and free of cancer (except non-melanoma
skin cancer) after the same amount of follow-up time as the
index case. An incidence density sampling protocol for
control selection was used, such that controls could include
participants who became a case later in time, while each
control participant could also be sampled more than once.
Matching criteria included recruitment center, age at
enrollment (±6 months), time of day of blood collection
(±1 h), follow-up time (as close as possible), time between
blood draw and last consumption of food or drinks (\3,
3–6,[6 h).
Laboratory assays
Plasma samples for phase 1 and phase 2 were analyzed for
genistein in 2007 and 2009, respectively, using ultra per-
formance liquid chromatography/tandem mass spectrome-
try (UPLC-MS/MS) in the HFL laboratory, Fordham,
Cambridgeshire, using an adaptation of a previously
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conducted the assays were blinded to the case or control
status of the participants. Plasma samples from each case–
control set were assayed within the same batch and ana-
lyzed on the same day.
Three HFL in-house quality control plasma samples
were inserted into each assay batch and analyzed in
duplicate. These quality control samples contained con-
centrations of genistein, which reﬂected low, medium, and
high ranges of the calibration chart (concentrations ranging
between 0.1 and 500 ng/ml, e.g., equivalent to
0.37–1,850 nmol/l genistein). The average intra-assay and
inter-assay coefﬁcients of variation (CVs) for genistein
were 3.1 and 4.1 %, respectively, in phase 1 samples, and
3.6 and 7.2 %, respectively, in phase 2 samples. An addi-
tional 108 ‘‘blinded’’ quality control samples from a pooled
plasma sample (mean genistein concentration, 6.7 ng/ml)
were included in phase 2; the average intra- and inter-assay
CVs for these samples were 12.3 and 16.0 %, respectively.
The lower limit of quantiﬁcation, equivalent to the
lowest point in the calibration curve, was 0.1 ng/ml; the
percentage of samples in which levels were not detectable
was 11.8 % overall (15.9 % in phase 1 samples and 5.6 %
in phase 2 samples). For individuals with levels below this
limit, genistein concentrations were imputed at half the
lower limit of detection, that is, 0.05 ng/ml.
Reproducibility study
To assess the appropriateness of a single measurement of
plasma genistein as a marker for long-term exposure to
plasma genistein in epidemiological studies, we examined
the reproducibility of genistein in plasma samples collected
from 100 men and 100 women from a UK-based EPIC-sub-
cohort, EPIC-Oxford. We measured circulating concen-
trations of plasma genistein in two samples from each of
the men collected approximately 5 years apart and calcu-
lated an intra-class correlation coefﬁcient (ICC) to assess
the reliability of the measurements. The intra-class corre-
lation coefﬁcient for plasma genistein was 0.32 (95 % CI
0.14, 0.50).
Statistical analysis
The concentrations of genistein in cases and controls were
compared using a weighted paired t test, comparing the
value for the case with the value in the matched control
participant, or the mean of the values in controls when
there were two matched controls in a set [11].
Conditional logistic regression models were applied to
calculatetherelativerisks(oddsratios)forprostatecancerin
relation to ﬁfths of genistein concentration using cut points
deﬁned by the quintiles among control participants for all
centerscombinedandusingthelowestcategoryasreference.
Likelihood ratio tests were used to assess heterogeneity, and
tests for linear trend were obtained using a continuous var-
iable with values equal to the median concentration within
each quintile of plasma genistein concentration.
To examine the effects of potential confounders (other
than the matching criteria, controlled for by design), the
analyses were repeated including additional variables in the
logistic regression models. These variables were smoking
(never, past, present), body mass index (BMI, kg/m
2;i n
fourths), physical activity (inactive, moderately inactive,
moderately active/active) (16), alcohol intake (\8, 8–15,
16–39, C40 g/day), marital status (married/cohabiting or
not married/cohabiting), and education level (primary or
equivalent, secondary, degree level). For each of these
variables, a small proportion of values was unknown
(\7 % of values missing for each, with the exception of
marital status, for which 32 % of values were missing);
these values were included in the analyses as a separate
category.
Likelihood ratio chi-squared tests were used to examine
the heterogeneity of the associations of genistein concen-
trations with risk of prostate cancer categorized according
to prostate tumor stage (localized or advanced), histologi-
cal grade (low grade or high grade), age at diagnosis (\60
and C60 years), and time to diagnosis (less than 4 years
after blood collection, four or more years after blood col-
lection). Likelihood ratio chi-squared tests were also used
to examine the heterogeneity of the associations of geni-
stein concentrations with prostate cancer risk for partici-
pants categorized by age at blood collection (\60 or
C60 years) and by country of recruitment (8 countries).
Statistical analyses were performed with the Stata 10
statistical software package [12]. The genistein concen-
trations were logarithmically transformed for statistical
analyses to approximately normalize their frequency dis-
tribution. All tests of statistical signiﬁcance were two-
sided, and p values below 0.05 were considered signiﬁcant.
Results
A total of 1,605 men diagnosed with prostate cancer from
recruitment until the end of follow-up and 1,697 matched
participants without prostate cancer were included in the
analyses. Their median age at blood collection was
60 years (range, 43–76 years).
When characteristics of case patients and control par-
ticipants were compared, the groups did not differ appre-
ciably, but there were some small differences (Table 1). A
comparison of the characteristics of cases and controls in
phase 1 and phase 2 did not show any clear differences
(results not shown).
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5.5 years after blood collection (range\1–15.1 years), and
the median age at diagnosis was 65 years (range,
44–85 years).
Table 2 shows the distribution of plasma concentrations
of genistein in controls in the eight countries participating
in the study. There was substantial variation in median
concentrations between the countries, with participants in
the UK and the Netherlands generally having the highest
concentrations of genistein and participants in Greece
having the lowest concentration.
When the distribution of plasma concentrations of
genistein in case patients and control participants were
compared, the differences between concentrations in cases
and controls were small in both phases (a difference of
0.3 ng/ml in both phases), and overall, there was no sig-
niﬁcant difference in genistein concentrations between
cases and controls (median concentration was 1.9 ng/ml in
both cases and controls, p = 0.20).
We examined the relative risks (RR) for prostate cancer
by plasma genistein concentration in phase 1 and in the
new samples from the 655 men with prostate cancer and
655 controls (phase 2), and in a combined sample of 1,605
cases and 1,697 controls (phases 1 and 2). In contrast to our
earlier study (phase 1), in phase 2 we observed a statisti-
cally signiﬁcant positive association between risk of pros-
tate cancer and concentration of genistein, with or without
adjustment for potential confounders (Table 3): compared
with men in the lowest ﬁfth of genistein concentration, men
in the highest ﬁfth had a RR of disease of 1.57 (95 % CI:
1.05, 2.33; p linear trend = 0.02). However, when data
from phase 1 and phase 2 were combined, there was no
signiﬁcant association: compared with the men in the
lowest ﬁfth of genistein concentration, men in the highest
ﬁfth had a RR of disease of 0.98 (95 % CI: 0.77, 1.23;
p linear trend = 0.95). Results were similar when the
analysis was additionally adjusted for smoking, BMI,
physical activity, alcohol intake, marital status, and edu-
cation level. There was no statistical evidence of hetero-
geneity in the trends in risk of prostate cancer according to
age at blood collection, body mass index, or country of
recruitment. In addition, there was no evidence of hetero-
geneity in the associations of genistein concentrations with
risk of prostate cancer categorized according to prostate
tumor stage, histological grade, age at diagnosis, or time to
diagnosis (Table 3).
We conducted three exploratory analyses in which we
deﬁned a baseline reference group as men with plasma
genistein less than 5 ng/ml (1,205 cases) and the highest
exposure groups with cut points of 20 ng/ml (83 cases),
30 ng/ml (43 cases), and 50 ng/ml (23 cases), respectively.
After adjustment for potential confounders, compared with
men in the baseline group (\5 ng/ml), men in the highest
Table 1 Characteristics of prostate cancer patients and control
participants
Characteristic Cases
(n = 1,605)
Controls
(n = 1,697)
Age at blood collection, years (SD) 60.2 (6.3) 60.0 (6.2)
Weight, kg (SD)
a 80.2 (11.3) 80.8 (12.0)
Height, cm (SD)
a 173.1 (7.0) 173.4 (6.9)
BMI, kg/m
2 (SD)
a 26.7 (3.4) 26.9 (3.6)
Smoking, % (n)
a
Never 32.7 (513) 31.3 (513)
Former 44.1 (693) 41.8 (684)
Current 23.2 (364) 26.9 (440)
Alcohol consumption, % (n)
a
\8 g/day 34.7 (549) 36.2 (598)
8–15 g/day 20.1 (318) 20.2 (334)
16–39 g/day 25.6 (405) 25.6 (423)
C40 g/day 19.5 (309) 18.0 (298)
Physical activity, % (n)
a
Inactive 19.0 (292) 18.0 (286)
Moderately inactive 32.7 (503) 31.5 (500)
Moderately active/active 48.4 (745) 50.5 (801)
Marital status, % (n)
a
Married or cohabiting 89.3 (971) 89.1 (1,040)
Not married or cohabiting 10.7 (116) 10.9 (127)
Educational attainment, % (n)
a
Primary or equivalent 37.2 (570) 38.9 (630)
Secondary 36.8 (564) 37.2 (602)
Degree 26.1 (400) 24.0 (388)
Cases only
Time to diagnosis, % (n)
b
\2 years 11.5 (184) –
2–\4 years 18.8 (302)
4–\6 years 26.5 (426)
6–\8 years 24.4 (392)
C8 years 18.8 (301)
Year of diagnosis,
median (range)
2001
(1994–2006)
–
Age at diagnosis, years (SD) 65.7 (6.3) –
Stage, % (n)
Localized 49.4 (792) –
Advanced 19.7 (316) –
Unknown 31.0 (497) –
Grade, % (n)
Low grade
c 58.6 (941) –
High grade
d 11.7 (188) –
Unknown 29.7 (476) –
Values are means, except where indicated
a Unknown for some participants; the calculations of percentages exclude
missing values
b Time between blood collection and diagnosis among case patients
c Gleason score\8 or coded as well or moderately differentiated
d Gleason score C8 or coded as poorly differentiated or undifferentiated
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respectively) had adjusted RRs for prostate cancer of 0.91
(0.67–1.24), 0.83 (0.54–1.27), and 0.96 (0.54–1.73) (data
not shown).
Discussion
In this large European prospective study, plasma concen-
tration of genistein was not associated with risk of prostate
cancer. Furthermore, there was no evidence for hetero-
geneity in the association by tumor stage or grade or other
factors. Strengths of the current analysis include the large
sample size and the varied dietary habits of the study
population, with the associated variation in plasma geni-
stein levels across the different countries participating in
the study (a 14-fold difference in concentration between
Greece and the Netherlands, the countries with the lowest
and highest levels, respectively) [13]. We are unable to
identify any material differences between participants in
phase 1 and phase 2 of our study besides time between
blood collection and diagnosis, age at diagnosis, and
country of recruitment (samples from Denmark and from
Umea in Sweden were not available for assaying in phase
2). Given the lack of heterogeneity in ﬁndings by these
factors and the relatively small sample sizes in each phase,
the marginally signiﬁcant but opposing associations we
observed in the two phases were most likely due to
chance.
The null ﬁndings from this current study are consistent
with ﬁndings from two smaller Japanese nested case–
control studies, which included 40 and 201 men with
prostate cancer, respectively [6, 7]. In the UK, results from
the EPIC-Norfolk cohort, including 191 cases [14], the
majority of whom are included in the current study, also
showed no signiﬁcant associations between serum con-
centrations of genistein and risk of prostate cancer. Our
results are also consistent with the ﬁndings from two recent
meta-analyses of dietary isoﬂavone intake in relation to
risk, both of which found no evidence of a signiﬁcant
association in non-Asian populations [1, 2]. Thus, our data
provide little support for a biologically relevant effect of
genistein as manifested in an association with prostate
cancer risk at a range of dietary exposures typical of
Western populations. There has been much discussion
about the levels of dietary phyto-estrogens needed to exert
a biological effect, and it may be that despite the over-
sampling of vegetarians and vegans in a British sub-cohort
of EPIC (EPIC-Oxford), levels of exposure are too low to
be biologically relevant [15]. The median circulating gen-
istein concentration in the top ﬁfth of the distribution in this
study, 14 ng/ml, is approximately seven times lower than
the average concentration of 99 ng/ml found in a study in
Japanese men [6]. In order to assess possible associations
with higher concentrations of plasma genistein, we con-
ducted three exploratory analyses, comparing risk among
men with plasma genistein greater or equal to 20, 30, and
50 ng/ml, respectively, with risk among a baseline group
with genistein concentrations less than\5 ng/ml. These cut
points yielded 83, 42, and 23 cases in the highest exposure
categories, respectively, and relative risks in these top
categories compared with the baseline group of 0.91
(0.67–1.24), 0.83 (0.54–1.27), and 0.96 (0.54–1.73). Thus,
even with higher plasma concentrations of genistein, there
is no evidence for an association, although of course there
are very small numbers with high levels of exposure
Table 2 Median (5th–95th percentile) concentrations of genistein
a among controls by country and study phase
Genistein
(ng/ml)
Denmark Germany Greece Italy Netherlands Spain Sweden UK Total
Phase 1
Number 288 201 9 62 25 93 186 178 1,042
Median
(5–95
percentile)
2.0
(0.05–23.8)
2.2
(0.05–23.5)
0.05
(0.05–17.2)
1.3
(0.05–10.3)
4.6
(0.2–40.1)
1.2
(0.05–7.4)
1.1
(0.05–14.9)
5.4
(0.2–41.5)
2.1
(0.05–24.5)
Phase 2
Number 0 211 31 84 25 108 0 196 655
Median
(5–95
percentile)
– 1.6
(0.1–13.7)
0.3
(0.05–5.0)
1.1
(0.05–5.7)
6.5
(1.5–26.2)
1.0
(0.05–4.9)
– 3.1
(0.1–24.0)
1.7
(0.05–16.1)
Total
Number 288 412 40 146 50 201 186 374 1,697
Median
(5–95
percentile)
2.0
(0.05–23.8)
1.9 (0.05–21) 0.3
(0.05–5.05)
1.15
(0.05–6.9)
5.2
(0.3–27.9)
1.2
(0.05–5.4)
1.1
(0.05–14.9)
4.3
(0.2–30.1)
1.9
(0.05–21.6)
a For participants with undetectable genistein levels, data were imputed at 0.05 ng/ml, half the lower limit of detection
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a for prostate cancer by ﬁfth of plasma genistein concentration, subdivided by selected
factors
Fifth of genistein concentration (ng/ml) p for
trend
c
p for
heterogeneity
of trends
d 1 (0.05–0.30) 2 (0.40–1.30) 3 (1.40–2.60) 4 (2.70–6.00) 5 (6.10–567.70)
Overall
Cases/controls (n) 338/357 326/333 282/329 326/344 333/334
RR (95 % CI) 1 (reference) 1.01 (0.81–1.26) 0.86 (0.68–1.09) 0.94 (0.74–1.19) 0.98 (0.77–1.23) 0.95
Adjusted RR (95 % CI)
b 1 (reference) 1.03 (0.82–1.29) 0.88 (0.69–1.12) 0.95 (0.75–1.21) 1.00 (0.79–1.27) 0.82
Study phase
Phase 1
Cases/controls (n) 217/219 205/209 171/201 185/205 172/208
Adjusted RR (95 % CI)
b 1 (reference) 1.00 (0.76–1.34) 0.81 (0.60–1.10) 0.80 (0.59–1.08) 0.74 (0.54–1.00) 0.05 \0.0001
Phase 2
Cases/controls (n) 121/138 124/126 118/129 137/135 155/127
Adjusted RR (95 % CI)
b 1 (reference) 1.20 (0.81–1.76) 1.12 (0.75–1.67) 1.26 (0.84–1.87) 1.57 (1.05–2.34) 0.03
Stage of disease
Localized stage
Cases/controls (n) 182/199 166/177 130/161 156/186 158/141
Adjusted RR (95 % CI)
b 1 (reference) 1.03 (0.76–1.41) 0.84 (0.60–1.19) 0.86 (0.62–1.20) 1.13 (0.81–1.57) 0.32 0.22
Advanced stage
Cases/controls (n) 67/71 61/56 57/61 66/67 65/73
Adjusted RR (95 % CI)
b 1 (reference) 1.20 (0.69–2.09) 0.98 (0.56–1.72) 0.96 (0.53–1.74) 0.88 (0.50–1.55) 0.42
Grade of disease
Low grade
Cases/controls (n) 219/214 189/208 148/192 193/206 192/204
Adjusted RR (95 % CI)
b 1 (reference) 0.84 (0.62–1.13) 0.67 (0.49–0.93) 0.79 (0.57–1.09) 0.79 (0.57–1.08) 0.50 0.26
High grade
Cases/controls (n) 37/47 32/28 37/40 41/44 41/35
Adjusted RR (95 % CI)
b 1 (reference) 1.45 (0.66–3.18) 1.28 (0.61–2.70) 1.04 (0.49–2.21) 1.57 (0.72–3.40) 0.36
Age at blood collection
\60 years
Cases/controls (n) 179/178 166/168 130/168 150/132 135/151
Adjusted RR (95 % CI)
b 1 (reference) 0.99 (0.73–1.36) 0.74 (0.53–1.06) 1.14 (0.80–1.63) 0.87 (0.61–1.24) 0.57 0.49
C60 years
Cases/controls (n) 150/151 154/153 147/155 174/202 194/176
Adjusted RR (95 % CI)
b 1 (reference) 1.00 (0.70–1.41) 0.94 (0.67–1.34) 0.82 (0.58–1.15) 1.10 (0.78–1.55) 0.36
Age at diagnosis
\60 years
Cases/controls (n) 72/72 51/59 54/54 53/46 47/54
Adjusted RR (95 % CI)
b 1 (reference) 0.95 (0.54–1.67) 1.01 (0.54–1.86) 1.20 (0.66–2.19) 0.74 (0.39–1.39) 0.35 0.80
C60 years
Cases/controls (n) 266/285 275/274 228/275 273/298 286/280
Adjusted RR (95 % CI)
b 1 (reference) 1.05 (0.82–1.34) 0.85 (0.65–1.10) 0.91 (0.70–1.18) 1.02 (0.79–1.33) 0.66
Time between blood collection and diagnosis
\48 months
Cases/controls (n) 100/104 80/94 92/95 94/78 110/112
Adjusted RR (95 % CI)
b 1 (reference) 0.96 (0.62–1.48) 1.03 (0.66–1.60) 1.25 (0.79–1.97) 1.02 (0.66–1.56) 0.97 0.86
C48 months
Cases/controls (n) 238/253 246/239 190/234 232/266 223/222
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pean populations.
Screening for prostate cancer with prostate-speciﬁc
antigen is not routinely performed in any of the EPIC
countries, although testing for prostate cancer by using the
serum concentration of prostate-speciﬁc antigen (PSA) has
become more widely used during the follow-up period of
the present study. Data on PSA use in the EPIC cohort are
not available, but studies of annual rates of PSA testing in
older middle-aged men in some of the participating coun-
tries suggest rates of 6 % in England and Wales, 7 % in
Netherlands, 9 % in Spain, and 16 % in Italy, compared
with approximately 38 % in US whites [16–20]. In the
current study, we had data on stage for 69 % of the cases,
of which 29 % (n = 316) were advanced; this is a higher
proportion than that in recent North American studies, but
it provided only a moderate sample size. When we inves-
tigated the relationship of plasma genistein with prostate
cancer risk subdivided by selected characteristics, includ-
ing tumor subtype, we found no evidence that the rela-
tionship between plasma genistein and prostate cancer risk
differed according to the characteristics of the tumors or
the participants, including stage or histological grade of the
disease and age at blood collection. These results contrast
with those from the case–control study nested within the
Japan Public Health Center-based Prospective Cohort
Study, which found a signiﬁcant inverse association
between circulating isoﬂavones and risk of localized
prostate cancer but not advanced stage disease [7]. How-
ever, the small numbers of participants in the subgroups in
this Japanese study (144 and 48 men with localized and
advanced stage disease, respectively) mean these ﬁndings
should be interpreted cautiously.
A limitation of this study is the use of a single mea-
surement of circulating genistein, rather than multiple
measurements, as a marker of isoﬂavone exposure. While
previous studies have shown that serum isoﬂavones are
good markers of dietary isoﬂavone intake [21], a single
measurement of circulating genistein in a Western
population with episodic and relatively low intake of iso-
ﬂavones may not be a very reliable indicator of long-term
exposure [22, 23]. Findings from two studies have sug-
gested that a single measure of circulating genistein may
not provide a good index of long-term exposure in popu-
lations from the USA (ICCs of 0.22 and 0.28, respectively,
for genistein measured in serum samples taken 1–2 years
apart) [22, 23]. Results from our reliability study in the
EPIC-Oxford sub-cohort are similar (ICC = 0.32). Thus,
measurement error due to the use of a single measurement
of circulating genistein concentration in our study may be
masking any association that exists with prostate cancer
risk.
In conclusion, the ﬁndings from this large prospective
study provide no evidence for an association between
concentrations of circulating genistein and risk of prostate
cancer in European men. The data presented illustrate the
challenges of studying the association between circulating
isoﬂavones and cancer risk in Western studies, in which
intake of dietary isoﬂavones is usually infrequent and rel-
atively low.
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Table 3 continued
Fifth of genistein concentration (ng/ml) p for
trend
c
p for
heterogeneity
of trends
d 1 (0.05–0.30) 2 (0.40–1.30) 3 (1.40–2.60) 4 (2.70–6.00) 5 (6.10–567.70)
Adjusted RR (95 % CI)
b 1 (reference) 1.08 (0.82–1.41) 0.82 (0.62–1.10) 0.85 (0.64–1.14) 0.98 (0.73–1.31) 0.97
a Case patients and control participants were matched on recruitment center, age at enrollment (±6 months), time of day of blood collection (±1 h),
follow-up time (as close as possible), time between blood draw, and last consumption of food or drinks (\3, 3–6,[6h )
b Adjustment was made for smoking (never, past, present), physical activity (inactive, moderately inactive, active), alcohol intake (\8, 8–15, 16–39,
C40 g/day), marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary, degree level), and BMI (fourths)
c Test for trend obtained by replacing the categorical variable with a continuous variable equal to the median concentration within each ﬁfth of plasma
genistein concentration
d Test for heterogeneity between the trends obtained by replacing the categorical variable with a continuous variable equal to the median concentration
within each ﬁfth of plasma genistein concentration
1170 Cancer Causes Control (2012) 23:1163–1171
123Conﬂict of interest The authors declare that they have no conﬂict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM (2009) Soy
food consumption and risk of prostate cancer: a meta-analysis of
observational studies. Nutr Cancer 61:598–606
2. Yan L, Spitznagel EL (2009) Soy consumption and prostate
cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr
89:1155–1163
3. Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC,
Bastian PJ (2008) Soy isoﬂavone genistein in prevention and
treatment of prostate cancer. Prostate Cancer Prostatic Dis
11:6–12
4. Liggins J, Mulligan A, Runswick S, Bingham SA (2002)
Daidzein and genistein content of cereals. Eur J Clin Nutr
56:961–966
5. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G,
Cassidy A (2003) Bioavailability of phyto-oestrogens. Br J Nutr
89(Suppl 1):S45–S58
6. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K
et al (2004) Serum phytoestrogens and prostate cancer risk in a
nested case-control study among Japanese men. Cancer Sci
95:65–71
7. Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S (2008)
Plasma isoﬂavones and subsequent risk of prostate cancer in a
nested case-control study: the Japan Public Health Center. J Clin
Oncol 26:5923–5929
8. Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW,
Overvad K et al (2009) Plasma phyto-oestrogens and prostate
cancer in the European Prospective Investigation into Cancer and
Nutrition. Br J Cancer 100:1817–1823
9. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M et al
(2002) European Prospective Investigation into Cancer and
Nutrition (EPIC): study populations and data collection. Public
Health Nutr 5:1113–1124
10. Grace PB, Mistry NS, Carter MH, Leathem AJ, Teale P (2007)
High throughput quantiﬁcation of phytoestrogens in human urine
and serum using liquid chromatography/tandem mass spectrom-
etry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life
Sci 853:138–146
11. Rosner B (1982) On the estimation and testing of interclass
correlations: the general case of multiple replicates for each
variable. Am J Epidemiol 116:722–730
12. StataCorp (2007) Stata statistical software: release 10. StataCorp
LP, College Station, TX
13. Peeters PH, Slimani N, van der Schouw YT, Grace PB, Navarro
C, Tjonneland A et al (2007) Variations in plasma phytoestrogen
concentrations in European adults. J Nutr 137:1294–1300
14. Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham
S (2008) Lack of prospective associations between plasma and
urinary phytoestrogens and risk of prostate or colorectal cancer in
the European Prospective into Cancer-Norfolk study. Cancer
Epidemiol Biomarkers Prev 17:2891–2894
15. McCarty MF (2006) Isoﬂavones made simple-genistein’s agonist
activity for the beta-type estrogen receptor mediates their health
beneﬁts. Med Hypotheses 66:1093–1114
16. D’Ambrosio G, Samani F, Cancian M, De Mola C (2004) Prac-
tice of opportunistic prostate-speciﬁc antigen screening in Italy:
data from the Health Search database. Eur J Cancer Prev
13:383–386
17. Melia J, Moss S, Johns L (2004) Rates of prostate-speciﬁc anti-
gen testing in general practice in England and Wales in asymp-
tomatic and symptomatic patients: a cross-sectional study. BJU
Int 94:51–56
18. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ,
Schroder FH et al (2003) Effective PSA contamination in the
Rotterdam section of the European randomized study of screen-
ing for prostate cancer. Int J Cancer 105:394–399
19. Paez A, Lujan M, Llanes L, Romero I, de la Cal MA, Miravalles
E et al (2002) PSA-use in a Spanish industrial area. Eur Urol
41:162–166
20. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann
PH et al (2002) Overdiagnosis due to prostate-speciﬁc antigen
screening: lessons from U.S. prostate cancer incidence trends.
J Natl Cancer Institute 94:981–990
21. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting
NP et al (2004) Phytoestrogen concentrations in serum and spot
urine as biomarkers for dietary phytoestrogen intake and their
relation to breast cancer risk in European Prospective Investiga-
tion of Cancer and Nutrition-Norfolk. Cancer Epidemiol Bio-
markers Prev 13:698–708
22. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Ton-
iolo P (1998) Reliability of serum measurements of lignans and
isoﬂavonoid phytoestrogens over a two-year period. Cancer Ep-
idemiol Biomarkers Prev 7:885–889
23. Fraser GE, Franke AA, Jaceldo-Siegl K, Bennett H (2010)
Reliability of serum and urinary isoﬂavone estimates. Biomarkers
15:135–139
Cancer Causes Control (2012) 23:1163–1171 1171
123